Critical care management for novel 2019 SARS-CoV-2 and HCoV-NL63 coinfection in a young immunocompromised patient: A Chicago experience

Authors

Alejandro Sanchez-Nadales, Advocate Aurora HealthFollow
Miguel Treminio Quezada, Advocate Aurora HealthFollow
Hasan Abad, Advocate Aurora HealthFollow
Jessica Navarro-Motta, Advocate Aurora HealthFollow
Pamela Contreras-Chavez, Advocate Aurora HealthFollow
Anil Kachru, Advocate Aurora HealthFollow
Chae Chu, Advocate Aurora HealthFollow

Recommended Citation

Sanchez-Nadales A, Treminio-Quezada M, Abad H, et al. Critical Care Management for Novel 2019 SARS-CoV-2 and HCoV-NL63 Coinfection in a Young Immunocompromised Patient: A Chicago Experience. Case Rep Crit Care. 2020;2020:8877641. Published 2020 Jul 31. doi:10.1155/2020/8877641

Affiliations

Advocate Illinois Masonic Medical Center,

Abstract

Background: SARS-CoV-2 is a newly emerged virus that has spread rapidly, exhibiting tremendous morbidity and mortality. Some potential pharmaceutical targets have been identified but are still lacking proper validation. Case Presentation. We describe the case of a young, immunosuppressed and critically ill patient with previous Influenza B infection, requiring extracorporeal membrane oxygenation, which was then followed, in the succeeding months, by SARS-CoV-2 infection complicated by severe adult respiratory distress syndrome. Her clinical course exhibited complications, including pulmonary embolism, acute kidney injury, pneumothorax, pneumomediastinum, multiple cardiac arrests, and eventually death.

Conclusion: Coinfection with other respiratory pathogens and opportunistic infections are possible.

Document Type

Article

PubMed ID

32802523